Antimalarial artesunate-mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
04 Jan 2024
04 Jan 2024
Historique:
received:
11
04
2023
accepted:
14
11
2023
medline:
5
1
2024
pubmed:
5
1
2024
entrez:
4
1
2024
Statut:
aheadofprint
Résumé
Schistosomiasis treatment entirely relies on a single drug, praziquantel, prompting research into alternative therapeutics. Here we evaluated the efficacy and safety of the antimalarial combination artesunate-mefloquine for the treatment of schistosomiasis in a proof-of-concept, pragmatic, open-label, randomized controlled trial in primary schools of six villages endemic for schistosomiasis in northern Senegal. Children (6-14 years) were eligible if Schistosoma eggs were detected by microscopy in urine and/or stool. In total, 726 children were randomized 1:1 to praziquantel (standard care: 40 mg kg
Identifiants
pubmed: 38177851
doi: 10.1038/s41591-023-02719-4
pii: 10.1038/s41591-023-02719-4
doi:
Banques de données
ClinicalTrials.gov
['NCT03893097']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Abajobir, A. A. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1211–1259 (2017).
doi: 10.1016/S0140-6736(17)32154-2
Colley, D. G., Bustinduy, A. L., Secor, W. E. & King, C. H. Human schistosomiasis. Lancet 383, 2253–2264 (2014).
pubmed: 24698483
pmcid: 4672382
doi: 10.1016/S0140-6736(13)61949-2
McManus, D. P. et al. Schistosomiasis. Nat. Rev. Dis. Primers 4, 13 (2018).
pubmed: 30093684
doi: 10.1038/s41572-018-0013-8
Bergquist, R., Utzinger, J. & Keiser, J. Controlling schistosomiasis with praziquantel: how much longer without a viable alternative? Infect. Dis. Poverty 6, 1–10 (2017).
doi: 10.1186/s40249-017-0286-2
Lai, Y.-S. et al. Spatial distribution of schistosomiasis and treatment needs in sub-Saharan Africa: a systematic review and geostatistical analysis. Lancet Infect. Dis. 15, 927–940 (2015).
pubmed: 26004859
doi: 10.1016/S1473-3099(15)00066-3
Lo, N. C. et al. Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. Lancet Infect. Dis. 22, e327–e335 (2022).
pubmed: 35594896
doi: 10.1016/S1473-3099(22)00221-3
Zwang, J. & Olliaro, P. L. Clinical efficacy and tolerability of praziquantel for intestinal and urinary schistosomiasis—a meta-analysis of comparative and non-comparative clinical trials. PLoS Negl. Trop. Dis. 8, e3286 (2014).
pubmed: 25412105
pmcid: 4238982
doi: 10.1371/journal.pntd.0003286
Zwang, J. & Olliaro, P. Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis. Parasit. Vectors 10, 47 (2017).
pubmed: 28126024
pmcid: 5270314
doi: 10.1186/s13071-016-1958-7
WHO. Assessing the Efficacy of Anthelminthic Drugs against Schistosomiasis and Soil-Transmitted Helminthiasis 1–29 (WHO, 2013).
Wu, W., Wang, W. & Huang, Y. X. New insight into praziquantel against various developmental stages of schistosomes. Parasitol. Res. 109, 1501–1507 (2011).
pubmed: 21984370
doi: 10.1007/s00436-011-2670-3
Crellen, T. et al. Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration. Clin. Infect. Dis. 63, 1151–1159 (2016).
pubmed: 27470241
pmcid: 5064161
Gardner, J. M. F., Mansour, N. R., Bell, A. S., Helmby, H. & Bickle, Q. The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult schistosoma species. PLoS Negl. Trop. Dis. 15, e0009490 (2021).
pubmed: 34280206
pmcid: 8321398
doi: 10.1371/journal.pntd.0009490
Saeed, M. E. M., Krishna, S., Johannes, H., Kremsner, P. G. & Efferth, T. Antischistosomal activity of artemisinin derivatives in vivo and in patients. Pharmacol. Res. 110, 216–226 (2016).
pubmed: 26902577
doi: 10.1016/j.phrs.2016.02.017
Abou-shady, O. M. Therapeutic effect of mefloquine on Schistosoma mansoni in experimental infection in mice. J. Parasit. Dis. 40, 259–267 (2016).
pubmed: 27413290
doi: 10.1007/s12639-014-0489-4
Utzinger, J., Tanner, M. & Keiser, J. ACTs for schistosomiasis: do they act? Lancet Infect. Dis. 10, 579–581 (2010).
pubmed: 20705514
doi: 10.1016/S1473-3099(10)70169-9
Keiser, J. et al. Efficacy and safety of mefloquine, artesunate, mefloquine–artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin. Infect. Dis. 50, 1205–1213 (2010).
pubmed: 20350194
doi: 10.1086/651682
Keiser, J. & Utzinger, J. Antimalarials in the treatment of schistosomiasis. Curr. Pharm. Des. 18, 3531–3538 (2012).
pubmed: 22607145
Perez del Villar, L., Burguillo, F. J., Lo, J., Muro, A. & Pe, L. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS ONE 7, e45867 (2012).
pubmed: 23029285
pmcid: 3448694
doi: 10.1371/journal.pone.0045867
Basra, A. et al. Efficacy of mefloquine intermittent preventive treatment in pregnancy against schistosoma haematobium infection in Gabon: a nested randomized controlled assessor-blinded clinical trial. Clin. Infect. Dis. 56, 68–75 (2013).
doi: 10.1093/cid/cis976
Keiser, J. et al. Praziquantel, mefloquine–praziquantel, and mefloquine–artesunate–praziquantel against Schistosoma haematobium: a randomized, exploratory, open-label trial. PLoS Negl. Trop. Dis. 8, e2975 (2014).
pubmed: 25033291
pmcid: 4102459
doi: 10.1371/journal.pntd.0002975
Sirima, S. B. et al. Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infect. Dis. 16, 1123–1133 (2016).
pubmed: 27430374
pmcid: 5030279
doi: 10.1016/S1473-3099(16)30020-2
Roucher, C. et al. Evaluation of artesunate–mefloquine as a novel alternative treatment for schistosomiasis in African children (SchistoSAM): protocol of a proof-of-concept, open-label, two-arm, individually-randomised controlled trial. BMJ Open 11, e047147 (2021).
pubmed: 34168029
pmcid: 8231067
doi: 10.1136/bmjopen-2020-047147
Léger, E. et al. Prevalence and distribution of schistosomiasis in human, livestock, and snail populations in northern Senegal: a One Health epidemiological study of a multi-host system. Lancet Planet Health 4, e330–e342 (2020).
pubmed: 32800151
pmcid: 7443702
doi: 10.1016/S2542-5196(20)30129-7
Bulletin Epidémiologique Annuel du Paludisme au Sénégal 2021 (Programme de Contrôle du Paludisme, 2022).
Karagiannis-Voules, D. A. et al. Spatial and temporal distribution of soil-transmitted helminth infection in sub-Saharan Africa: a systematic review and geostatistical meta-analysis. Lancet Infect. Dis. 15, 74–84 (2015).
pubmed: 25486852
doi: 10.1016/S1473-3099(14)71004-7
Sartorius, B. et al. Prevalence and intensity of soil-transmitted helminth infections of children in sub-Saharan Africa, 2000–18: a geospatial analysis. Lancet Glob. Health 9, e52–e60 (2021).
pubmed: 33338459
doi: 10.1016/S2214-109X(20)30398-3
Liu, R., Dong, H., Guo, Y., Zhao, Q. & Jiang, M. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and. Parasit. Vectors 4, 201 (2011).
pubmed: 22004571
pmcid: 3207908
doi: 10.1186/1756-3305-4-201
Schlagenhauf, P. et al. Use of mefloquine in children—a review of dosage, pharmacokinetics and tolerability data. Malar. J. 10, 292 (2011).
pubmed: 21981927
pmcid: 3215676
doi: 10.1186/1475-2875-10-292
Lee, S. J., Ter Kuile, F. O., Price, R. N., Luxemburger, C. & Nosten, F. Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: a pooled analysis of 19, 850 individual patients. PLoS ONE 12, 1–16 (2017).
Degarege, A. et al. Plasmodium falciparum infection status among children with schistosoma in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Negl. Trop. Dis. 10, 1–18 (2016).
doi: 10.1371/journal.pntd.0005193
WHO Guidelines for Malaria. 14 March 2023 (World Health Organization, 2023)
Cohee, L. M. et al. Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses. Lancet Glob. Health 8, e1499–e1511 (2020).
pubmed: 33222799
pmcid: 7721819
doi: 10.1016/S2214-109X(20)30325-9
Cissé, B. et al. Effectiveness of seasonal malaria chemoprevention in children under ten years of age in Senegal: a stepped-wedge cluster-randomised trial. PLoS Med. 13, 1–18 (2016).
doi: 10.1371/journal.pmed.1002175
Cairns, M. et al. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: case–control studies in 5 countries. PLoS Med. 18, e1003727 (2021).
pubmed: 34495978
pmcid: 8457484
doi: 10.1371/journal.pmed.1003727
Balikagala, B. et al. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 385, 1163–1171 (2021).
pubmed: 34551228
doi: 10.1056/NEJMoa2101746
Plowe, C. V. Malaria chemoprevention and drug resistance: a review of the literature and policy implications. Malar. J. 21, 104 (2022).
pubmed: 35331231
pmcid: 8943514
doi: 10.1186/s12936-022-04115-8
Kattenberg, J. H. et al. Malaria molecular surveillance in the peruvian amazon with a novel highly multiplexed Plasmodium falciparum AmpliSeq assay. Microbiol. Spectr. 11, e0096022 (2023).
pubmed: 36840586
doi: 10.1128/spectrum.00960-22
Olliaro, P. L. et al. Toward measuring schistosoma response to praziquantel treatment with appropriate descriptors of egg excretion. PLoS Negl. Trop. Dis. 9, e0003821 (2015).
pubmed: 26086551
pmcid: 4473103
doi: 10.1371/journal.pntd.0003821
Hatz, C. The use of ultrasound in schistosomiasis. Adv. Parasitol. 48, 225–284 (2001).
pubmed: 11013757
doi: 10.1016/S0065-308X(01)48007-9
Webster, J. P., Koukounari, A., Lamberton, P. H. L., Stothard, J. R. & Fenwick, A. Evaluation and application of potential schistosome-associated morbidity markers within large-scale mass chemotherapy programmes. Parasitology 136, 1789–1799 (2009).
pubmed: 19523252
doi: 10.1017/S0031182009006350
Hofmann, N. et al. Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med. 12, e1001788 (2015).
pubmed: 25734259
pmcid: 4348198
doi: 10.1371/journal.pmed.1001788
Kattenberg, J. H. et al. Molecular surveillance of malaria using the PF AmpliSeq custom assay for plasmodium falciparum parasites from dried blood spot DNA isolates from Peru. Bio Protoc. 13, e4621 (2023).
pubmed: 36908639
pmcid: 9993081
doi: 10.21769/BioProtoc.4621
Gryseels, B. et al. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop. Med Int. Health 6, 864–873 (2001).
pubmed: 11703840
doi: 10.1046/j.1365-3156.2001.00811.x
Meurs, L. et al. Epidemiology of mixed Schistosoma mansoni and Schistosoma haematobium infections in northern Senegal. Int J. Parasitol. 42, 305–311 (2012).
pubmed: 22366733
doi: 10.1016/j.ijpara.2012.02.002
Meurs, L. et al. Micro-geographical heterogeneity in Schistosoma mansoni and S. haematobium infection and morbidity in a co-endemic community in Northern Senegal. PLoS Negl. Trop. Dis. 26, e2608 (2013).
doi: 10.1371/journal.pntd.0002608
Mbow, M. et al. T-helper 17 cells are associated with pathology in human schistosomiasis. J. Infect. Dis. 207, 186–195 (2013).
pubmed: 23087431
doi: 10.1093/infdis/jis654
Mbow, M. et al. Changes in immunological profile as a function of urbanization and lifestyle. Immunology 143, 569–577 (2014).
pubmed: 24924958
pmcid: 4253505
doi: 10.1111/imm.12335
Meurs, L. et al. Is PCR the next reference standard for the diagnosis of schistosoma in stool? A comparison with microscopy in Senegal and Kenya. PLoS Negl. Trop. Dis. 28, e0003959 (2015).
doi: 10.1371/journal.pntd.0003959
Huyse, T. et al. Evolutionary epidemiology of schistosomiasis: linking parasite genetics with disease phenotype in humans. Int. J. Parasitol. 48, 107–115 (2018).
pubmed: 29154994
doi: 10.1016/j.ijpara.2017.07.010
Boon, N. A. M. et al. No barrier breakdown between human and cattle schistosome species in the Senegal River Basin in the face of hybridisation. Int. J. Parasitol. 49, 1039–1048 (2019).
pubmed: 31734338
doi: 10.1016/j.ijpara.2019.08.004